A peptide drug conjugate is a type of drug molecule that combines a peptide with another molecule, such as a small molecule drug or a protein, to create a new compound. The resulting conjugate has properties of both the peptide and the other molecule, which allows for targeted delivery of the drug to specific cells or tissues in the body, increasing efficacy and reducing side effects.
Peptides are short chains of amino acids that can bind to specific receptors on cells, making them ideal for targeted drug delivery. By conjugating a peptide with another molecule, such as a chemotherapy drug or a diagnostic imaging agent, the resulting molecule can be specifically targeted to cells that express the receptor for the peptide.
The conjugation process typically involves attaching the other molecule to the peptide using a linker molecule. This linker can be designed to be cleaved under certain conditions, such as in the presence of enzymes in the target tissue, which releases the drug at the desired location. Based on our new analysis at insightSLICE, the global peptide drug conjugates market size was estimated to be $575 million in 2021 and is expected grow at a CAGR of 16% between 2023 and 2032 to reach global size of US$ 2920 million. Below, I’ll delve into the factors and key trends driving the market.
Factors Driving The Global Peptide Drug Conjugate Market
Increasing Prevalence Of Chronic Diseases
Chronic diseases such as cancer, diabetes, and autoimmune disorders are often difficult to treat with traditional drugs due to their complex nature and the difficulty in targeting specific cells or tissues. Peptide drug conjugates offer a more targeted approach to treatment, delivering the drug payload more precisely and reducing the likelihood of side effects. The increasing prevalence of chronic diseases is driving the development and use of peptide drug conjugates in several ways. According to the WHO, chronic diseases account for approximately 71% of all deaths worldwide, with cardiovascular diseases alone responsible for 17.9 million deaths per year. Similarly, the American Hospital Association reports that approximately 133 million Americans, which is nearly 50% of the population, have at least one chronic illness such as heart disease, hypertension, or arthritis. This figure has increased by 15 million over the past decade, and it is projected to rise to 170 million by 2030.